Mikhail Blagosklonny started his career with his education first, getting a M.D. in Internal Medicine and PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg. He went on to become associate professor of medicine in 2002, at New York Medical College in Valhalla, New York. Afterward he went to the Ordway Research Institute in Albany, New York, until 2007, where he became a part of Roswell Park Cancer Institute and is there to this day.
His current position at Roswell is Associate Member of the Department of Cell Stress Biology and Associate Professor of Oncology. Blagosklonny’s research program’s area of concentration is several aspects of molecular biology, drug resistance of melanoma, and blood malignancies. His lab is active in following the development of small molecule inhibitors of C-MYC, an oncogenic transcription factor that is over copied in more than 80% of human cancer. In plainer terms, Blagosklonny studies cancer and also aging.
Blagosklonny has a hypothesis about the role and ability that TOR signaling in cancer and aging, and proposes in using rapamycin, which is a popular cancer drug, as a possibility in extending a human life. He is passionate in urging for the use of rapamycin in researching how to prolong life.
Mikhail Blagosklonny has published over 270 papers, in peer-reviewed journals with over 25,000 citations. He is editor-in-chief of Aging, Cell Cycle, and Oncotarget, and associate editor of Cancer Biology & Therapy, and on the editorial board as a member for Cell Death & Differentiation. His work is considered controversial by some, but his work is brilliant and funded by the National Cancer Institute and the American Cancer Society. The future holds possibilities of lengthening life, and maybe curing cancer. View Mikhail’s profile on Google Scholar